ARWR Arrowhead Pharmaceuticals, Inc. - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
ARWR Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$63.27
Analyst Target
$81.36
+28.6%
Upside
52W High
$76.76
52W Low
$9.57
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
75%
Analysis Accuracy
ARWR's Piotroski F-Score of 4/9 indicates weak financial health, with a notable debt-to-equity ratio of 1.24 and lack of Altman Z-Score data suggesting potential distress risk. However, the company exhibits exceptional growth momentum with a 10,461% YoY revenue surge and strong profitability metrics including a 75.5% ROE and 18.5% profit margin. Despite a high valuation (P/E of 39.54 and Price/Sales of 8.12), the stock trades at a premium justified by aggressive growth expectations. Insider selling activity is bearish, but analyst consensus remains buy with a target price of $81.36, reflecting strong forward confidence. Price trades at a 464.9% premium to fair value estimate ($11.20), limiting near-term upside from a valuation perspective.
Key Strengths
Exceptional 10,461% YoY revenue growth, signaling strong market traction
High profitability with 75.5% ROE and 18.5% profit margin despite biotech sector norms
Strong gross margin of 100.00%, indicating high product pricing power or low cost structure
Positive earnings surprise history with average 43.67% beat over last 4 quarters
Analyst consensus is buy with a $81.36 target, implying 28.6% upside from current price
Key Risks
Piotroski F-Score of 4/9 indicates weak financial health and potential operational instability
Debt/Equity ratio of 1.24 is elevated for a biotech firm, raising leverage concerns
Insider selling of $32.12M in last 6 months signals potential internal skepticism
Forward P/E of -14.72 reflects negative earnings expectations, undermining valuation sustainability
Lack of Altman Z-Score and missing cash/debt data prevent full assessment of bankruptcy risk
AI Fair Value Estimate
Based on comprehensive analysis
$11.2
-82.3% below current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare ARWR against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning ARWR from our newsroom.
Newest → oldest
No matching news yet.